Introduction
============

Abnormalities involving *JAK2* (9p24) have been seen in B-ALL, but most often via point mutations involving the pseudokinase domain, R683 \[[@B1],[@B2]\]. Rearrangements of 9p24, however, are rare, with only a small number of cases reported in the literature involving the following loci and partner genes: 22q11.2 (unknown gene), 12p13 (*ETV6*), 5p14.1 (*SSBP2*), 8p22 (*PCM1*), and 9p13.2 (*PAX5*) \[[@B1],[@B3]\]. Activation of *JAK2* occurs via gene fusions encoding chimeric proteins in which the kinase domain of *JAK2* is fused to another cellular gene that provides a dimerization or oligomerization interface to the *JAK2* kinase domain, leading to constitutive activation \[[@B1]-[@B5]\]. This case pinpoints the fact that *JAK2* rearrangements may play an important role in the pathogenesis of lymphoblastic leukemias. To the best of our knowledge, this is one of the few cases with rearrangements of *JAK2* with chromosome 12p11.2 as well as rearrangements of *MLL* involving chromosome 6q27, both with unknown partner genes.

Case presentation
=================

A 13-year-old male presented with abdominal pain and fevers for three months. He was found to have leukocytosis (WBC 76.5x103/uL), anemia (Hgb 5.3 g/dL), and thrombocytopenia (platelet count 15.3x103/uL). Flow cytometry on peripheral blood revealed 94% blasts which expressed bright CD10, CD19, partial CD20, CD34, partial CD38, partial TdT, CD79a, and HLA-DR. A bone marrow biopsy showed a hypercellular marrow extensively involved (\~95%) by sheets of lymphoblasts. These findings are consistent with a diagnosis of B-lymphoblastic leukemia. The patient was immediately started on induction chemotherapy with AALL0232 high-risk ALL chemotherapy protocol. A follow-up bone marrow biopsy on day 29 showed minimal residual disease (MRD). A normal karyotype was seen in all metaphase cells examined and loss of one copy of the 5′IGH@ was the only abnormality detected in 2.7% of the interphase nuclei studied. The patient subsequently was given treatment per clinical trial AALL0031 and achieved primary remission. Most recently, the patient received a successful allogeneic bone marrow transplant from a female donor.

Methods
=======

Cytogenetics
------------

Chromosome analysis was performed using standard cytogenetic techniques on bone marrow and peripheral blood, analyzing 20 metaphase cells. Karyotypes were prepared using Applied Imaging CytoVision software 2013 nomenclature \[[@B6]\].

FISH
----

Fluorescence in situ hybridization (FISH) was performed on interphase nuclei and previously G-banded metaphases using the RP11-927H16 Spectrum Green JAK2 probe (Empire Genomics, 700 Michigan Ave, suite 200, Buffalo, NY 14203) and the following probes: Vysis LSI MLL Dual Color Break Apart Probe, Vysis LSI ETV6 Dual Color Break Apart, Vysis LSI ETV6(TEL)/RUNX1(AML1) ES Dual Color Translocation Probe Set and Vysis LSI IGH Dual Color, Break Apart Rearrangement Probe from Abbott Molecular (Des Plaines, Illinois 60018).

Findings
========

Cytogenetics
------------

Chromosome analysis of the bone marrow showed 5 of 20 cells with an *MLL* insertion on 6q27 as well as a balanced translocation between 9p24 and 12p11.2 (Figure [1](#F1){ref-type="fig"}). The same abnormalities were seen on a karyotype performed on peripheral blood, though at a lower frequency (1 of 20 cells).

![Abnormal karyotype seen on G-banded chromosomes in the bone marrow: 46,XY,ins(6;11)(q27;q23q23),t(9;12),(p24;p11.2)\[5\]/46,XY\[15\].](2050-7771-1-31-1){#F1}

In light of the FISH findings the karyotype of the bone marrow of this patient was described as: **46,XY,ins(6;11)(q27;q23q23),t(9;12),(p24;p11.2)\[5\]/46,XY\[15\]**.

FISH
----

FISH analysis using interphase nuclei showed *MLL* split signals in 23.6% (71/300) of the nuclei examined, suggestive of an *MLL* (11q23) gene rearrangement (Figure [2](#F2){ref-type="fig"}). However, FISH performed on previously G-banded metaphases also helped to identify two separate clonal populations with different *MLL* abnormalities: one with an *MLL* rearrangement mentioned above and one with an *MLL* insertion on chromosome 6q27 (Figure [3](#F3){ref-type="fig"}). Additionally, a deletion of the 5′ IGH@ region, corresponding to the variable segment of the IGH@ was seen in 88.3% (265/300) of the nuclei analyzed which may suggest a deletion of this region or an unbalanced rearrangement involving chromosome 14q32 (Figure [4](#F4){ref-type="fig"}).

![**Split*MLL*signals elucidated by FISH on interphase nuclei.**](2050-7771-1-31-2){#F2}

![***MLL*insertion on 6q27 elucidated by FISH on previously G-banded metaphase chromosomes.**](2050-7771-1-31-3){#F3}

![**Deletion of*5′ IGH@*elucidated by FISH on interphase nuclei.**](2050-7771-1-31-4){#F4}

FISH using the BAC RP11-927H16 probe (*JAK2*) showed a *JAK2* signal on the normal copy of chromosome 9, a *JAK2* signal on the short arm of chromosome 12, and a *JAK2* signal on the derivative chromosome 9 (Figure [5](#F5){ref-type="fig"}). Because there were no abnormalities involving *ETV6* (12p13), confirmed by using the Vysis LSI ETV6(TEL)/RUNX1(AML1) ES Dual Color Translocation Probe Set on interphase cells (Figures [6](#F6){ref-type="fig"}) and the Vysis LSI ETV6 Dual Color Break Apart on metaphase cells (Figure [7](#F7){ref-type="fig"}), the breakpoints on chromosome 12 were defined as 12p11.2 (Figure [7](#F7){ref-type="fig"}).

![**FISH on metaphases using the BAC RP11-927H16 (*JAK2*) showed a signal on the normal copy of chromosome 9, a*JAK2*signal on the short arm of chromosome 12, and a*JAK2*signal on the derivative chromosome 9.**](2050-7771-1-31-5){#F5}

![**There was no evidence of*ETV6/RUNX1*translocation by interphase FISH.**](2050-7771-1-31-6){#F6}

![**There was no evidence of*ETV6*rearrangements by metaphase FISH.**](2050-7771-1-31-7){#F7}

The constellation of these results was described as:

nuc ish(MLLx2)(5′MLL sep 3′MLLx1)\[71/300\].

nuc ish(ETV6,RUNX1)x2\[300\] .ish (5′ETV6,3′ETV6)x2(5′ETV6 con 3′ETV6x2).

nuc ish(3′IGH\@x2,5′IGHx1) (3xIGH\@con 5′IGH\@x1) \[265/300\].

Discussion
==========

The findings in this case - *MLL* rearrangements, abnormalities of the *IGH@,* 12p abnormalities, and rearrangements of 9p24 involving the *JAK2* locus - have been previously described in B-ALL \[[@B1]-[@B3]\]. Abnormalities involving *IGH@* have only been recently identified as a biologically and clinically relevant sub-group of B-ALL \[[@B7]\]. However deletions of the 5′ *IGH@* region have not been well characterized in B-ALL in conjunction with *JAK2* rearrangements and *MLL* abnormalities. *JAK2* translocations have been reported in B-ALL, although at low frequencies. These B-ALL patients are most often male, present with hyperleukocytosis, respond poorly to chemotherapy, often relapse, and tend to have little to no cytogenetic abnormalities apart from those involving *JAK2*\[[@B1]\]. This fact may suggest that *JAK2* rearrangements play a driving role in the leukemogenesis of B-ALL.

*JAK2* translocations induce dimerization or oligomerization of *JAK2* without ligand binding, resulting in constitutive activation of *JAK2*-mediated tyrosine kinase pathways. It has been speculated that other cytogenetic abnormalities occurring in conjunction with *JAK2* rearrangements in B-ALL may recruit other altered tyrosine kinase pathways that in turn, lead to an inferior clinical outcome. A correlation has also been observed between *CRLF2* (cytokine receptor-like factor 2) overexpression and *JAK2* mutations, most likely because *CRLF2* is a *JAK*-binding, Box 1 motif-containing cytokine receptor. Increased expression of *CRLF2* independently has been correlated with a poor prognosis in B-ALL, and the synergistic effects of *CRLF2* overexpression and *JAK2* constitutive activation may play a major role in the leukemogenesis of the disease that can be prognostically considered and therapeutically targeted \[[@B8]\]. Similarly, even point mutations and rearrangements in the *CRFL2* gene have been reported to activate aberrant *JAK2* signaling \[[@B9]\].

While *JAK2* translocations are not common in lymphoblastic leukemia, it is clear that newly developed small molecular *JAK2* inhibitors such as TG101348 and TG10129 developed by TargetGen, Inc. show promising results in blocking the action of mutated *JAK2* in myeloproliferative disorders \[[@B2],[@B10]\]. There are at least 10 different *JAK* inhibitors undergoing various phases of clinical trials \[[@B11]\] including a group of TKIs used for both MPDs and non-MPDs, namely MK-0457 (previously VX-680), that has had *JAK2* inhibitory action in MPD and reduced kinase activity in T315I-positive ALL and CML \[[@B2]\]. Lestaurtinib I(CEP-701), used mainly for myeloid malignancies, has also been used in a clinical trial to treat children with B-ALL \[[@B11]\]. However, among neoplasias dependent on tyrosine kinases, treatment with ATP-mimetic inhibitors has invariably resulted in the development of inhibitor resistance mutations \[[@B9]\]. A novel *JAK2* inhibitor, NVP_BVB808 (BVB808), has been used experimentally in mice xenografted with human B-ALL to recover E864K, Y931C, and G935R mutations within the kinase domain of *JAK2* that confer resistance to multiple *JAK2* enzymatic inhibitors \[[@B9]\]. In addition, treatment with inhibitors of heat shock protein 90 (HSP90) has now been used experimentally to overcome all three resistance mutations and potentially kill cells dependent on *JAK2*. However, development of new therapies that target the abnormal *JAK2* tyrosine kinase activity may benefit patients diagnosed with ALL presenting with *JAK2* rearrangements \[[@B9]\].

Structural abnormalities involving the *MLL* gene (11q23) with various partner genes have been reported in ALL in \~6% of cases, but an *MLL* insertion at 6q27 has not been reported to the best of our knowledge \[[@B12]\]. Herein, conventional and molecular cytogenetic metaphase analysis solely revealed an insertion of *MLL* on chromosome 6q27 with an unknown fusion partner gene; however, further molecular cytogenetic studies on interphase nuclei unveiled a second clonal population of cells harboring an *MLL* rearrangement. Inversion of *MLL* may, however, have followed rearrangements with chromosome 6 (as opposed to preceding it). Limited sample material prevented further molecular characterization. Furthermore, *MLL* insertions have been reported to result in chimeric fusion genes and are usually associated with a poor prognosis \[[@B3],[@B12]\].

In short, our case highlights the importance of using multiple tools, namely conventional cytogenetic and molecular genetic analysis, to elucidate complex rearrangements involving *JAK2* and *MLL* genes. The detection and therapeutic targeting of *MLL* as well as *JAK2* abnormalities in cases of ALL may be prognostically beneficial as they may represent a distinct subtype of acute lymphoblastic leukemia. To the best of our knowledge, this study is the first reported case of a pediatric B-ALL that shows a concurrent *MLL* gene rearrangement with a *JAK2* translocation and deletion of the 5′ *IGH@* region. This case sheds light on the potential significance of *JAK2* and *MLL* as prognostic and therapeutic targets in lymphoblastic leukemias, and suggests further investigation to determine the benefits of the newly developed *JAK2* inhibitors against translocations involving *JAK2* in pediatric B-ALL*.*
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